关键词: 奥氮平, 精神分裂症, 认知功能, 安全性

Abstract:

Objective To analyze the effect of olanzapine on relevant scoring of schizophrenia in patients, including the adverse reaction scale (TESS), the Positive and Negative Syndrome Scale (PANSS), the Mini Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA), severity of illness (SI); as well as the effect of olanzapine on related factors such as neurobiochemical markers, S100beta protein (S100β), intermediate filament and associated protein, repetin (Rptn), fasting plasma glucose (FPG), 2-h postprandial blood glucose (2hPG), ect. Methods Totally 82 schizophrenic inpatients from March 2018 to January 2020 were selected and divided into two groups as different medication schemes after admission. The observation group was treated with drug intervention of olanzapine and the control group with drug intervention of aripiprazole. Before and after treatment, the levels of S100β, Rptn, FPG and 2hPG was measured, PANSS score, MMSE score, MOCA score, SI score and TESS score were compared between groups. Results There was no significant difference in S100β, Rptn, FPG, 2hPG between groups before treatment (P>0.05). Rptn was higher (P<0.05) and S100β, FPG, 2hPG was lower (P<0.05) in observation group when compared with control group, respectively. Difference of PANSS, MMSE, MoCA, SI scores was no significant between groups before treatment (P>0.05). PANSS, SI scorces in observation group were lower than those in control group (P<0.05) and MMSE, MoCA scores higher than those in control group (P<0.05). There was no significant difference in TESS scores between groups before treatment (P>0.05). TESS scores on weeks 6, week 8 post-treatment in observation group were lower than those in control group (P<0.05). Conclusion PANSS score decreases significantly by the application of olanzapine for schizophrenia, which is capable improving patient's cognitive function, and with high safety.

Key words: olanzapine, schizophrenia, cognitive function, security